Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003077 · ClinicalTrials.gov registry record · Phase 1
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
A Phase 1 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT00003077: Completed Phase 1 study, sponsored by Alliance for Clinical Trials in Oncology.
NCT00003077 is a Phase 1 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 63 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003077, a Phase 1 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
RATIONALE: Omega-3 fatty acids are used by the body for energy and tissue development and may be an effective treatment for patients with advanced cancer who are unable to maintain their body weight. PURPOSE: Phase I/II trial to study the effectiveness of omega-3 fatty acids in treating patients with advanced cancer who have significant weight loss.
Interventions
- DIETARY_SUPPLEMENT omega-3 fatty acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 1995-10 |
| Est. Completion | 2004-11 |
| Phase | Phase 1 |
What the finished NCT00003077 record still lists
NCT00003077 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which omega-3 fatty acid is the first listed.
NCT00003077 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003077 about?
NCT00003077 is a clinical study titled "Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss". RATIONALE: Omega-3 fatty acids are used by the body for energy and tissue development and may be an effective treatment for patients with advanced cancer who are unable to maintain their body weight. PURPOSE: Phase I/II trial to study the effectiveness of omega-3 fatty acids in treating patients wi...
What is the current status of trial NCT00003077?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 1995-10. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00003077?
The interventions under investigation include: omega-3 fatty acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00003077?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003077's enrollment target sits among peer trials
63 820th of 2000 higher than 1,177 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia